贝伐珠单抗在结直肠癌中的疗效及不良反应探讨

Study on the Efficacy and Adverse Reactions of Bevacizumab in Colorectal Cancer

目的探讨在治疗结直肠癌中贝伐珠单抗的临床效果和不良反应情况。方法纳入该院于2018年7月—2020年7月阶段收治的70例中晚期结直肠癌患者,采用随机数表法均分为研究组和对照组。对照组行FLOFOX化疗方案,研究组在上述基础上加行贝伐珠单抗。记录两组临床疗效和安全性。结果研究组治疗后其客观缓解率40.00%,高于对照组(17.14%),两组对比差异有统计学意义(χ^(2)=4.480,P=0.034);研究组的Ⅲ~Ⅳ级胃肠道不适反应为3例(8.57%),血液学毒性反应发生6例(17.14%);对照组Ⅲ~Ⅳ级胃肠道不适反应为4例(11.43%),血液学毒性反应发生2例(20.00%),两组对比差异无统计学意义(χ^(2)=0.764,P=0.382)。结论贝伐珠单抗应用于结直肠癌中,有利于患者临床疗效的提升,且不会导致不良反应的增加。

Objective To investigate the clinical effects and adverse reactions of bevacizumab in the treatment of colorectal cancer.Methods A total of 70 patients with advanced colorectal cancer who were admitted to the hospital between July 2018 and July 2020 were enrolled.They were divided into study group and control group by random number table method.The control group received FLOFOX chemotherapy,and the study group received bevacizumab on the above basis.The clinical efficacy and safety of the two groups were recorded.Results After treatment,the objective remission rate of the study group was 40.00%,which was higher than of the control group(17.14%).The difference between the two groups was statistically significant(χ^(2)=4.480,P=0.034);the levelⅢ~Ⅳgastrointestinal discomfort of the study group was 3 cases(8.57%),and the incidence of hematological toxicity was 6 cases(17.14%);the control groupⅢ~Ⅳgastrointestinal discomfort was 4 cases(11.43%),and the incidence of hematological toxicity was 2 cases(20.00%),the comparison of the two groups was not statistically significantly difference(χ^(2)=0.764,P=0.382).Conclusion The use of bevacizumab in colorectal cancer is beneficial to the improvement of the clinical efficacy of patients,and will not lead to an increase in adverse reactions.